OVARIAN CANCER

This early-phase study tested a vaccine called DCP-001 in 17 women with a specific type of ovarian cancer (high-grade serous) who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cel…

This study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that no longer responded to standard platinum chemotherapy. The goal was to see if the combination could shrink tumors and how safe it was. Participants took the drugs by mouth a…

This study tested a new approach for advanced ovarian cancer: giving the immunotherapy drug nivolumab directly into the abdomen (intraperitoneally) after surgery and heated chemotherapy (HIPEC). The goal was to see if this combination is safe and tolerable. Twenty-two adults with…

This study tested a new drug called IMP4297 in 93 adults with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has stopped responding to at least two prior chemotherapies. The goal was to see if the drug could shrink tumors and how safe it was. The drug is take…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced solid tumors including breast, ovarian, stomach, colorectal, brain, bile duct, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if…

This study allowed people with certain cancers (ovarian, basal cell, or colorectal) who had already shown benefit from the drug vismodegib in earlier trials to keep receiving it. The main goal was to track safety and side effects over time. Only 19 patients took part, all of whom…

This study tested an experimental drug called ZN-c3, given alone or with another drug (niraparib), in 117 people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to find safe doses and see if the treatment could shrink tumors or slow the di…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian, fallopian tube, or primary peritoneal cancer that does not have a BRCA mutation. Over 1,300 pa…

This study tested whether adding the drug BD0801 to standard chemotherapy helps women with recurrent ovarian cancer that no longer responds to platinum-based treatment. The trial included 421 women with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The…

This early-phase study tested a new drug called CUE-102 in 42 adults with advanced colorectal, gastric, pancreatic, or ovarian cancers that had stopped responding to standard treatments. Participants had a specific genetic marker (HLA-A*0201) and their tumors produced a protein c…

This early-stage study tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, or lung cancer) that had stopped responding to standard treatments. The drug is a nanoparticle version of a chemotherapy agent, given through an IV, and the m…

This study tested a combination of two drugs, NT-I7 and pembrolizumab, in 215 people with advanced solid tumors that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combo could shrink tumors. The study included people with several…

This early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, or colon cancer. The main goals were to check safety, find the best dose, and see if the drugs help control the disease. Participant…

This early-phase study tested a new treatment called Radspherin® in 21 people with recurrent ovarian cancer that had spread in the abdomen. The treatment involves injecting tiny radioactive particles directly into the belly after surgery to remove visible tumors. The main goals w…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers that had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can reduce canc…

This phase 2 study tested a drug called mirvetuximab soravtansine in 79 people with recurrent ovarian, peritoneal, or fallopian tube cancer that had high levels of a protein called folate receptor-alpha. The cancer had come back after platinum-based chemotherapy but was still sen…

This study tested whether the immunotherapy drug pembrolizumab could help keep ovarian cancer from growing after initial chemotherapy. Twenty women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer received weekly paclitaxel followed by pembrolizumab as mainte…

This study tested whether adding immunotherapy drugs (durvalumab with or without tremelimumab) to standard chemotherapy before surgery is safe and feasible for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 69 participants received these treatme…

This study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that had stopped responding to platinum chemotherapy and had already been treated with a PARP inhibitor. The goal was to see if the combo could slow or stop cancer growth. The…

This early-phase trial tested an experimental drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based treatments. The main goals were to check safety and find the best dose. …

This study tested whether zafirlukast, an asthma drug, can control ovarian cancer that is only detected by rising CA-125 levels in the blood. Five women with this type of relapse took the drug to see if it could lower their CA-125 levels. The goal was to delay or prevent further …

This study tested a drug called nirogacestat in 53 people with a rare type of ovarian cancer that had come back after treatment. The goal was to see if the drug could shrink tumors or stop them from growing. Researchers measured how many patients had their tumors shrink and how l…

This early-phase study tested an experimental drug called VS-6766, given by mouth on different schedules, in 104 adults with advanced solid tumors or multiple myeloma. The goal was to find a safe and tolerable dose, both when used alone and when combined with another drug (everol…

This early-stage study tested a new drug called RP903 in 69 people with advanced solid tumors (like ovarian, breast, or cervical cancer) who had no other treatment options. The main goal was to check the drug's safety and find the right dose, not to cure the cancer. While some pa…

This study looked at 120 women over 70 with advanced ovarian cancer who were considered vulnerable due to age and health. It compared three chemotherapy plans: standard two-drug therapy, a single drug, or a weekly low-dose combination. The goal was to see which plan allowed patie…

This study looked at 221 women with ovarian cysts who were scheduled for surgery. Researchers tested two blood markers (CA125 and HE4) and two scoring methods (ROMA and RMI) to see which could best tell apart benign (non-cancerous) from malignant (cancerous) tumors. The goal was …

This study looked at whether fluid taken from the space behind the vagina (cul-de-sac) can help diagnose ovarian cancer. Researchers measured two tumor markers, CA-125 and HE4, in that fluid from 52 women about to have surgery for a suspicious ovarian mass. They also checked a ur…

This study explored whether a non-invasive light technique (Raman spectroscopy) can detect ovarian cancer in blood samples and identify active cancer in tissue after chemotherapy. Researchers analyzed samples from 160 women with symptoms or undergoing treatment. The goal is to im…

This study looked at two ways to manage ovarian cancer risk in 40 women with BRCA gene mutations or strong family history. One group had their ovaries and fallopian tubes removed to prevent cancer, while the other group had regular CA-125 blood tests to catch cancer early. Resear…

This study tested whether adding the drug aprepitant to standard anti-nausea medicines could better prevent nausea and vomiting caused by chemotherapy in 143 women with gynecologic cancers like ovarian or cervical cancer. Participants received either the three-drug combo or a pla…

This study tested whether giving a low dose of esketamine during ovarian cancer surgery could prevent or reduce depressive symptoms that often occur after the procedure. Over 500 women undergoing cytoreductive surgery received either esketamine or a placebo, and their mood was ch…

This study looked at whether acupressure, a technique where you apply gentle pressure to specific points on the body, can help reduce severe tiredness (fatigue) in women who have had ovarian cancer. 171 survivors who had finished their main cancer treatments (like surgery and che…

This study tested a mobile app that lets ovarian cancer patients report their symptoms and well-being to their care team. The goal was to help doctors make better decisions and improve patients' quality of life. Ten women with advanced ovarian, fallopian tube, or primary peritone…

This study tested a home-based brain training program for 60 women who had finished chemotherapy for gynecologic cancers (like ovarian or uterine cancer) and were experiencing memory or thinking problems. Participants used a computer program called BrainHQ for 10 weeks. The goal …

This study looked at the safety of the cancer drug olaparib in over 1,000 Chinese patients with ovarian or prostate cancer. Researchers tracked side effects and how doctors managed them in everyday medical practice. The goal was to better understand the drug's real-world safety p…

This study checked if olaparib, a drug for advanced ovarian or breast cancer, leads to low folate (folic acid) levels in the blood. Ten postmenopausal women were followed to see how many developed folate deficiency and when it happened. The goal was to understand a possible side …

This study looked at whether a special website or two phone calls with a health coach could encourage more people with a personal or family history of certain cancers to get genetic testing. Over 800 adults who already completed a family health survey were randomly assigned to on…

This study looked at whether a care plan led by a geriatrician and a trained nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

This study looked at 386 women with cervical, uterine, or ovarian cancer to compare complication rates between standard laparoscopic surgery and robot-assisted laparoscopic surgery. The goal was to see which approach leads to fewer problems within the first six months after the o…

This study tested a digital health platform designed to help people with a genetic mutation for hereditary breast and ovarian cancer communicate test results with their relatives. Researchers worked with 128 participants in Switzerland and Korea to see if the tool could reduce di…

This study checked how often fallopian tube removal (salpingectomy) is incomplete when done as part of ovary removal surgery. Researchers looked at tissue samples from 115 women to see if any tube tissue was left behind. They also aimed to create a training video to help surgeons…

This study looked at medical records from 509 adults in Taiwan to find out how often a protein called HER2 IHC 3+ appears in advanced endometrial, ovarian, and cervical cancers. The goal was to better understand these cancers and help guide future treatment options. No new treatm…

This study tested a new automated method to grow cancer cells from patients inside chicken eggs. Researchers used samples from 101 people with metastatic cancers like prostate, breast, and lung cancer. The goal was to see if the automated system could successfully grow tumors at …

This study looks at how well the drug T-DXd works compared to usual treatments for people with advanced HER2-positive solid tumors (like lung, colon, and ovarian cancers). Researchers will use data from past clinical trials and real-world patient records to compare survival rates…

This study followed 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking niraparib as a maintenance treatment to keep their cancer from coming back. Researchers observed how well patients tolerated the drug in everyday clinical practice, without g…

This study looked at whether following national guidelines for ovarian cancer surgery is cost-effective. Researchers measured the cost per quality-adjusted life year (QALY) over three years in 200 women with advanced ovarian cancer. The goal was to see if sticking to guidelines p…

This study tested a new follow-up approach for people treated for gynecologic cancers like ovarian, endometrial, cervical, or vulvar cancer. Instead of seeing a doctor every time, patients met with a nurse at every other visit and used a smartphone app to learn self-management sk…

This study tested different ways to encourage genetic testing in people at high risk for breast or ovarian cancer. Over 1,300 participants received either a direct message through an online patient portal or a reminder to their doctor during a visit. The goal was to see which met…

This study looked at tumor cells found in the blood of 30 women with advanced ovarian cancer. Researchers counted these cells and studied their features to see if they relate to how the disease progresses. The goal is to develop a simple blood test to help monitor the cancer and …

This study tested if a green dye (ICG) can help surgeons find the first lymph nodes that might show if ovarian cancer has spread. 48 women having surgery for an ovarian mass or to lower their cancer risk took part. Doctors injected the dye in three different ways and used a speci…

This study looked at whether hospitals that follow specific quality standards for advanced ovarian cancer surgery have better patient outcomes. Researchers reviewed records from over 11,000 patients treated at specialized centers across Europe. The goal was to see if sticking to …

This study tested a digital tool (a chatbot) to help cancer survivors learn about genetic testing for hereditary cancer risk. 50 adults who had certain cancers (like breast, ovarian, or prostate) took part. The goal was to see if the chatbot was easy to use and if it helped more …

This study followed 354 people with ovarian cancer who were taking niraparib (Zedula) capsules daily as part of their normal care. The main goal was to watch for side effects like low blood cell counts, high blood pressure, and other serious issues over one year. Researchers did …